Overview

Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection

Status:
Terminated

Trial end date:
2018-04-01

Target enrollment:

Participant gender:

Summary

This study will test the safety and tolerability of HCV Entry Inhibitor ITX 5061 in Liver Transplant Recipients with Hepatitis C infection. The investigators hypothesize that ITX 5061 oral monotherapy will be safe in adults during and after liver transplantation and that therapy will also inhibit HCV infection of newly transplanted livers in adults with prior HCV infection.

Phase:

Phase 1

Details

Lead Sponsor:

Schiano, Thomas D., MD

Collaborator:

iTherX Pharmaceuticals Inc.